Sign In
Buy AKRO
$54.65
+0 (+0%)
At Close: Mar 06, 2026
A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH
11:40pm, Wednesday, 29'th Mar 2023
NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient po
89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease
09:14am, Wednesday, 22'nd Mar 2023
Small biotech company 89bio scored a win Wednesday in fatty liver disease, and ETNB stock rocketed well above its 50-day moving average. The post 89bio Rockets 30% — And Akero Dives — On A Scorchi
Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
08:00am, Wednesday, 04'th Jan 2023
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious meta
Akero Therapeutics: What Is Making The Stock Tick
11:01am, Wednesday, 23'rd Nov 2022
In September, AKRO went up on solid phase 2b data. MDGL, which also has strong phase 2 data, is toplining phase 3 by next month but has a lower valuation.
Are Medical Stocks Lagging Akero Therapeutics (AKRO) This Year?
11:27am, Monday, 07'th Nov 2022
Here is how Akero Therapeutics, Inc. (AKRO) and AVEO Pharmaceuticals (AVEO) have performed compared to their sector so far this year.
These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022
09:21pm, Monday, 24'th Oct 2022
The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.
These Are the Five Best and Worst Performing Small-cap Stocks in September 2022
08:02pm, Friday, 21'st Oct 2022
Small-cap stocks are usually young companies that aspire to become large-cap or mega-cap one day.
These Were The Five Best And Worst Performing Healthcare Stocks In September 2022
07:41pm, Monday, 17'th Oct 2022
September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.
Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference
04:01pm, Tuesday, 11'th Oct 2022
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious met
Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year?
11:17am, Wednesday, 05'th Oct 2022
Here is how Akero Therapeutics, Inc. (AKRO) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.
Akero Therapeutics: A Promising NASH Innovator
09:47am, Sunday, 18'th Sep 2022
Despite the recent resurgence, many biotech innovators are still trading at a fraction of their intrinsic value. In studying the biotech landscape, I recently uncovered another promising innovator dub
Akero Therapeutics: Outstanding Data In NASH
04:08pm, Thursday, 15'th Sep 2022
Akero Therapeutics recently posted solid phase 2b data. Akero appears adequately funded.
Akero Therapeutics (AKRO) Up on Positive Data from NASH Study
02:59pm, Wednesday, 14'th Sep 2022
Akero Therapeutics (AKRO) reports positive top-line data from a mid-stage study evaluating its lead candidate, efruxifermin (EFX), in patients with NASH, fibrosis stage 2 or 3 (F2-F3). Stock up.
Akero Therapeutics' Positive NASH Trial Results And Cash Raise
08:17am, Wednesday, 14'th Sep 2022
Akero Therapeutics reported positive mid-stage NASH trial results. Akero immediately announced a stock offering to raise cash.
Why Akero Therapeutics Stock Is on Fire Today
11:04am, Tuesday, 13'th Sep 2022
The biotech's experimental NASH drug hit the mark in a key phase 2b trial.
